CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia
Jie Liu,
Mengyuan Xu,
Xiaoqian Zhang,
Zhuo Zhang,
Tao Zhong,
Hongjuan Yu,
Yueyue Fu,
Hongbin Meng,
Jiawei Feng,
Xindi Zou,
Xueying Han,
Liqing Kang,
Lei Yu,
Limin Li
Affiliations
Jie Liu
Department of Hematology, The First Affiliated Hospital, Harbin Medical University, The Institute of the Hematology and Oncology of Heilongjiang Province, Harbin, Heilongjiang, PR China
Mengyuan Xu
Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China
Xiaoqian Zhang
Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China
Zhuo Zhang
Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China
Tao Zhong
Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China
Hongjuan Yu
Department of Hematology, The First Affiliated Hospital, Harbin Medical University, The Institute of the Hematology and Oncology of Heilongjiang Province, Harbin, Heilongjiang, PR China
Yueyue Fu
Department of Hematology, The First Affiliated Hospital, Harbin Medical University, The Institute of the Hematology and Oncology of Heilongjiang Province, Harbin, Heilongjiang, PR China
Hongbin Meng
Department of Hematology, The First Affiliated Hospital, Harbin Medical University, The Institute of the Hematology and Oncology of Heilongjiang Province, Harbin, Heilongjiang, PR China
Jiawei Feng
Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China
Xindi Zou
Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China
Xueying Han
Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China
Liqing Kang
Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, PR China
Lei Yu
Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, PR China
Limin Li
Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, The Institute of the Hematology and Oncology of Heilongjiang Province, Harbin, Heilongjiang, PR China; Corresponding author. Department of Hematology, South University of Science and Technology Hospital, Shenzhen, 518000, Guangdong, PR China.
Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy remain a subject of debate. In this research we investigated the efficiency and long-term outcomes of CD19 CAR-T bridging with allo-HSCT in R/R B-ALL patients. A total of 42 patients were brought into the cohort studies. Our findings revealed that patients who appected CAR-T followed by HSCT had a 1-year overall survival (OS) rate of 70 % and a 1-year leukemia-free survival (LFS) rate of 95 %. Moreover, patients who underwent this combined treatment had higher OS and LFS rates compared to those who received CAR-T therapy alone. In conclusion, the results of this clinical trial provide compelling evidence for the safety and efficacy of using CAR-T therapy as a bridging strategy to allo-HSCT in patients with R/R B-ALL.
